Showing results (81-90 of 118) with videos related to

Sort By:
Pageof 12
International Journal of Clinical Oncology|September 1, 2025
Epidermal growth factor receptor inhibitor-related skin toxicities: a review of management and possible preventive and therapeutic approaches for Asian patients by the Japanese Pharmacist-led Oncodermatology Study TeamYohei Iimura, Hirotoshi Iihara, Yoshitaka Saito, et al.
Anticancer Research|March 31, 2021
Primary Prophylaxis of Febrile Neutropenia With Pegfilgrastim in Small-cell Lung Cancer Patients Receiving Amrubicin as Second-line TherapyYukina Sato, Hirotoshi Iihara, Motohiko Kinomura, et al.
BMC Cancer|March 24, 2022
Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysisSenri Yamamoto, Hirotoshi Iihara, Ryuji Uozumi, et al.
BMC Cancer|July 20, 2021
Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trialsSenri Yamamoto, Hirotoshi Iihara, Ryuji Uozumi, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 2, 2026
Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancerRonald Chow, Daniel Zhang, Samy Kannout, et al.
Anticancer Research|February 28, 2023
Effect of Mirtazapine for the Prevention of Nausea and Vomiting in Patients With Thoracic Cancer Receiving Platinum-based ChemotherapyMotohiko Kinomura, Hirotoshi Iihara, Hironori Fujii, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 14, 2020
Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapyChiemi Hirose, Hironori Fujii, Hirotoshi Iihara, et al.
The Oncologist|April 3, 2021
Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II TrialChizuru Sakai, Mototsugu Shimokawa, Hirotoshi Iihara, et al.
Molecular and Clinical Oncology|March 7, 2022
Cancer cachexia as a determinant of efficacy of first-line pembrolizumab in patients with advanced non-small cell lung cancerHironori Fujii, Ayumu Araki, Hirotoshi Iihara, et al.
Anticancer Research|May 31, 2022
Control and Risk Factors of Nausea and Vomiting in Patients With Cervical Cancer Receiving RadiotherapyAkane Uno, Senri Yamamoto, Hirotoshi Iihara, et al.
Pageof 12